Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer

The goal of this observational study is to learn about the occurrence of and to identify suitable strategies for screening and monitoring of inner ear damage in patients receiving cisplatin chemoradiotherapy for head and neck cancer. Researchers will compare patients who are receiving cisplatin chemoradiotherapy to patients who are only receiving radiotherapy. Patients will undergo standardized testing for hearing loss, tinnitus and vestibular dysfunction at baseline, during and after treatment. Optional genetic analyses will aim to identify genes known to predispose to cisplatin-induced ototoxicity.

NCT Number	NCT06929468
Lead Sponsor	Simon Jäger Collaborators: Klinikum Nürnberg
Conditions	Ototoxic Hearing Loss, Ototoxicity, Drug-Induced, Cisplatin-induced Hearing Loss, Cisplatin Ototoxicity, Head and Neck Cancer, Dizzyness, Inner Ear Hearing Loss, Vestibular Disease +3 more
Enrollment	55 participants
Start Date	2025-07
Primary Completion	2027-06 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2025-04-16